Filtered By:
Source: Toxicology Letters
Condition: Fatty Liver Disease (FLD)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Upregulation of hepatic CD36 via glucocorticoid receptor activation contributes to dexamethasone-induced liver lipid metabolism disorder in mice
Toxicol Lett. 2022 May 16:S0378-4274(22)00091-1. doi: 10.1016/j.toxlet.2022.05.003. Online ahead of print.ABSTRACTGlucocorticoids such as dexamethasone (DEX) are widely prescribed to treat numerous conditions and diseases. However, glucocorticoid-induced liver lipid metabolism disorder, even nonalcoholic fatty liver disease, has caused extensive attention. Since fatty acid transporters such as CD36 and FATP play crucial roles in hepatic fatty acid uptake, this work examined their potential involvement in DEX-induced liver lipid accumulation. Chronic DEX administration (1-5mg/kg/day over 28 days) induced hepatic lipid accum...
Source: Toxicology Letters - May 19, 2022 Category: Toxicology Authors: Mingyang Chen Mengru Bai Yaodong Yi Shuanghui Lu Jun Luo Ping Li Hengbin Zhang Huidi Jiang Hui Zhou Source Type: research
